R.E.C. Henrar

EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

Hans R. Hendriks, P. E. Pizao, Dan Berger et al. · European Journal of Cancer · 1993 · 104 citations

Tumor Biology, Preclinical Models, Medicine +7

Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

Albert A. Geldof, S.C. Mastbergen, R.E.C. Henrar et al. · Cancer Chemotherapy and Pharmacology · 1999 · 68 citations · Full text

Neuro-oncology, Marine Biotechnology, Vitro Assays +9

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Hilde Rosing, M. J. X. Hillebrand, José Jimeno et al. · Journal of Mass Spectrometry · 1998 · 49 citations

Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe

S.S. Buttles, David R. Newell, R.E.C. Henrar et al. · European Journal of Cancer · 1995 · 39 citations

Preclinical Toxicology, Preclinical Drug Evaluation, Medicine +9

Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent

Hans R. Hendriks, Jacqueline Plowman, Dan Berger et al. · Annals of Oncology · 1992 · 35 citations · Full text

Animal Toxicology Studies, Preclinical Antitumour Activity, Toxinology +10